Nevro Balance Sheet Health
Financial Health criteria checks 4/6
Nevro has a total shareholder equity of $293.1M and total debt of $211.5M, which brings its debt-to-equity ratio to 72.1%. Its total assets and total liabilities are $635.7M and $342.6M respectively.
Key information
72.1%
Debt to equity ratio
US$211.47m
Debt
| Interest coverage ratio | n/a |
| Cash | US$322.72m |
| Equity | US$293.15m |
| Total liabilities | US$342.57m |
| Total assets | US$635.71m |
Recent financial health updates
Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?
Feb 25
Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?
Nov 16Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?
Jul 10Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?
Jan 13Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?
Oct 02Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?
Jun 17Recent updates
Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?
Feb 25There Is A Reason Nevro Corp.'s (NYSE:NVRO) Price Is Undemanding
Jan 08Is Nevro (NYSE:NVRO) Using Debt In A Risky Way?
Nov 16Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold
Sep 01Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?
Jul 10Investors Shouldn't Be Too Comfortable With Nevro's (NYSE:NVRO) Robust Earnings
Feb 28Nevro falls to 52-week low; down ~49% over last year
Feb 22Nevro: Treating Patient Back Pains, Causing Shareholder Back Pains
Feb 14Does Nevro (NYSE:NVRO) Have A Healthy Balance Sheet?
Jan 13Nevro: Opportunity Overshadowed By Weaknesses
Dec 07Boston Scientific drives rival Nevro lower after remarks on neuromodulation
Oct 26Nevro's Senza spinal cord stimulation system for chronic pain gets FDA approval
Oct 13Nevro gets FDA approval for Costa Rica manufacturing operations
Oct 04Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?
Oct 02Nevro: Niche Operator In Neuropathy, Reluctant Hold On Valuation
Sep 07Is Nevro (NYSE:NVRO) Weighed On By Its Debt Load?
Jun 17Nevro: FDA Approved Lower Back Pain Relief Without Opiates Or Surgery
Jun 10Nevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?
Feb 07Nevro: A Top Recovery Play As Covid Abates
Jan 04Financial Position Analysis
Short Term Liabilities: NVRO's short term assets ($530.9M) exceed its short term liabilities ($83.4M).
Long Term Liabilities: NVRO's short term assets ($530.9M) exceed its long term liabilities ($259.2M).
Debt to Equity History and Analysis
Debt Level: NVRO has more cash than its total debt.
Reducing Debt: NVRO's debt to equity ratio has increased from 62.1% to 72.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NVRO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if NVRO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.